However, spironolactone did reduce the major burden faced by these patients -- the risk of repeated hospitalizations for heart failure.

Spironolactone is used to treat fluid retention in patients with congestive heart failure, liver cirrhosis or nephrotic syndrome.

The aldosterone inhibitor, spironolactone, is not being used properly in patients with heart failure in everyday clinical practice, resulting in an unnecessary higher rate of adverse effects ...

However, spironolactone did reduce the major burden faced by these patients—the risk of repeated hospitalizations for heart failure.

In the RALES trial, this drug was useful in low doses for severe heart failure, but doctors are now using it more broadly than recommended with less follow-up and more complications.

Research indicates that spironolactone may reduce rehospitalizations and 30-day mortality in patients with acute heart failure (AHF).

Spironolactone is a medicine that is really old. It's been around for decades. And it is classified pharmacologically as a diuretic, even though its diuretic effect at the doses we use in heart ...

Although the mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone (Inspra, Pfizer) have been shown to be beneficial in patients with heart failure (HF) with reduced ejection ...

More research is needed to further explore the potential for spironolactone, a blood pressure medication, to prevent heart failure and its long-term impact on an individual’s heart health after ...

Research Highlights: The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart ...

Spironolactone is used to treat fluid retention in patients with congestive heart failure, liver cirrhosis or nephrotic syndrome.

However, spironolactone did reduce the major burden faced by these patients—the risk of repeated hospitalizations for heart failure.